BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO– Hagens Berman
SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and …